Cargando…
Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393273/ https://www.ncbi.nlm.nih.gov/pubmed/30206825 http://dx.doi.org/10.1007/s41669-018-0096-x |
| _version_ | 1783398650630635520 |
|---|---|
| author | Lee, D. Amadi, A. Sabater, J. Ellis, J. Johnson, H. Kotapati, S. McNamara, S. Walker, A. Cooper, M. Patterson, K. Roskell, N. Meng, Y. |
| author_facet | Lee, D. Amadi, A. Sabater, J. Ellis, J. Johnson, H. Kotapati, S. McNamara, S. Walker, A. Cooper, M. Patterson, K. Roskell, N. Meng, Y. |
| author_sort | Lee, D. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6393273 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-63932732019-03-15 Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England Lee, D. Amadi, A. Sabater, J. Ellis, J. Johnson, H. Kotapati, S. McNamara, S. Walker, A. Cooper, M. Patterson, K. Roskell, N. Meng, Y. Pharmacoecon Open Correction Springer International Publishing 2018-09-11 /pmc/articles/PMC6393273/ /pubmed/30206825 http://dx.doi.org/10.1007/s41669-018-0096-x Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Correction Lee, D. Amadi, A. Sabater, J. Ellis, J. Johnson, H. Kotapati, S. McNamara, S. Walker, A. Cooper, M. Patterson, K. Roskell, N. Meng, Y. Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England |
| title | Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England |
| title_full | Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England |
| title_fullStr | Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England |
| title_full_unstemmed | Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England |
| title_short | Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England |
| title_sort | correction to: can we accurately predict cost effectiveness without access to overall survival data? the case study of nivolumab in combination with ipilimumab for the treatment of patients with advanced melanoma in england |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393273/ https://www.ncbi.nlm.nih.gov/pubmed/30206825 http://dx.doi.org/10.1007/s41669-018-0096-x |
| work_keys_str_mv | AT leed correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT amadia correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT sabaterj correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT ellisj correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT johnsonh correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT kotapatis correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT mcnamaras correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT walkera correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT cooperm correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT pattersonk correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT roskelln correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland AT mengy correctiontocanweaccuratelypredictcosteffectivenesswithoutaccesstooverallsurvivaldatathecasestudyofnivolumabincombinationwithipilimumabforthetreatmentofpatientswithadvancedmelanomainengland |